Current Appointments & Affiliations
Professor of Medicine
·
2020 - Present
Medicine, Medical Oncology,
Medicine
Chief, Division of Medical Oncology
·
2021 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2019 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Intracranial Progression-Free Survival Correlates with Overall Survival and Varies by Tumor Subtype in Patients with Breast Cancer and Brain Metastases.
Journal Article Neuro Oncol · May 12, 2026 BACKGROUND: Brain metastases in patients with breast cancer (BCBM) are common. While the Breast Graded Prognostic Assessment (Breast GPA) predicts overall survival (OS), its ability to predict intracranial progression-free survival (icPFS) has not been est ... Full text Link to item CiteDESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.
Journal Article Clin Cancer Res · March 16, 2026 PURPOSE: Establish the safety, tolerability, and preliminary activity of trastuzumab deruxtecan (T-DXd) in combination with other anticancer therapies in human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer (mBC). PATIENTS AND METHO ... Full text Link to item CiteQuantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.
Journal Article NPJ Precis Oncol · March 13, 2026 Trastuzumab deruxtecan (T-DXd) is commonly used for treating metastatic breast cancer (MBC); however, traditional HER2 immunohistochemistry has largely failed to predict T-DXd activity. We reviewed survival outcomes and tested the reliability of multiple H ... Full text Link to item CiteRecent Grants
Asciminib in HER2+ Breast Cancer Brain Metastases (ASCENdANT)
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2026 - 2031IZABRIGHT-Breast01: A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician's Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Meta
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2026 - 2031Phase 2 Study of Zelenectide Pevedotin in Participants with NECTIN4 Amplified Advanced Breast Cancer
Clinical TrialPrincipal Investigator · Awarded by BicycleTx Limited · 2025 - 2030View All Grants
Education
East Carolina University, Brody School of Medicine ·
2002
M.D.